Adeno-associated virus variant capsids and use for inhibiting angiogenesis
US11766489B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 26, 2018 |
| Grant date | Sep 26, 2023 |
| Priority date | — |
| Expiry date | Apr 20, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14145
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.